NCT06973291: An ongoing trial by Takeda
This trial is ongoing. It must report results 11 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06973291 |
|---|---|
| Title | A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 9, 2025 |
| Completion date | April 22, 2026 |
| Required reporting date | April 22, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |